ReviewUrologie (Heidelberg, Germany)2025
[Urothelial carcinoma of the upper and lower urinary tract-which risk factors make early detection worthwhile?]
Review in Urologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations between PM2.5 exposure and upper tract urothelial carcinoma in a taiwanese case-control study.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinoma is one of the most common malignancies both in Germany and worldwide. Due to the frequent occurrence of late-onset or nonspecific symptoms, carcinomas are often diagnosed at advanced stages. Structured early detection programs have the potential to detect urothelial carcinoma in earlier stages and to improve survival rates. Various risk factors are associated with urothelial carcinoma, most notably tobacco abuse and occupational exposure, as well as genetic disorders such as Lynch syndrome in upper urinary tract carcinoma. In clinical practice, diagnostic tools include general examinations and ultrasound imaging of the urinary tract, with microhematuria and urine cytology playing key roles. For screening purposes noninvasive urine markers have demonstrated limited evidence. Despite the lack of optimal diagnostic markers for systematic early detection in high-risk populations, it is essential to ensure that every patient presenting with hematuria undergoes appropriate and risk-adapted diagnostics.
Indexed as
Identifiers
39589482What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.